Drug Profile
Research programme: anti-Vn human monoclonal antibodies - Crucell
Alternative Names: Anti-vitronectin human monoclonal antibodies research programme - Crucell; Research programme: anti-vitronectin human monoclonal antibodies - Crucell; Vn18Latest Information Update: 27 Jan 2005
Price :
$50
*
At a glance
- Originator Crucell
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Jan 2005 Discontinued - Preclinical for Cancer in Netherlands (unspecified route)
- 11 Feb 2002 Preclinical development for Cancer in Netherlands (Unknown route)